Dr. Julie S. Shepard

Pediatrics
Office
7200 Poe Ave Ste 200, 
Dayton, OH 
Office
7200 Poe Ave Ste 200, 
Dayton, OH 

Overview

Julie Shepard is a Pediatrics provider practicing medicine in Dayton, Ohio.

Her clinical expertise encompasses Measles.

She is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 11 clinical trials.

Specialties

Pediatrics

Licenses

Pediatrics in OH

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Office
7200 Poe Ave Ste 200, Dayton, OH 45414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Biological
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
Impact of Infant Formula on Caregiver-perceived Intolerance
Impact of Infant Formula on Caregiver-perceived Intolerance
Enrollment Status: Completed
Publish Date: June 09, 2020
Intervention Type: Other
Study Phase: Not Applicable
Acceptance Of A Partially-Hydrolyzed Infant Formula
Acceptance Of A Partially-Hydrolyzed Infant Formula
Enrollment Status: Completed
Publish Date: January 09, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 9 Less Clinical Trials

10 Total Publications

Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Journal: The New England journal of medicine
Published: September 17, 2025
Similar Doctors
Expertise in
4
conditions
Expertise in
4
conditions
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (51.3 miles away)
513-636-4261
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Margaret Collins is a Pediatrics provider practicing medicine in Cincinnati, Ohio. Dr. Collins is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Esophagitis, Viral Gastroenteritis, Pulmonary Alveolar Proteinosis, Endoscopy, and Tissue Biopsy. Dr. Collins is currently accepting new patients.

Expertise in
207
conditions
Dr. Robert J. Hopkin
Medical Genetics | Pediatrics
Expertise in
207
conditions
Dr. Robert J. Hopkin
Medical Genetics | Pediatrics
Referral may be required

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (51.3 miles away)
513-636-4200
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Robert Hopkin is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Cincinnati, Ohio. Dr. Hopkin is highly rated in 207 conditions, according to our data. His clinical expertise encompasses Fabry Disease, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Micrognathia, and Orchiectomy. Dr. Hopkin is currently accepting new patients.

Expertise in
2
conditions
Expertise in
2
conditions
Referral may be required

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (51.3 miles away)
513-636-6771
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marc Rothenberg is a Pediatrics provider practicing medicine in Cincinnati, Ohio. Dr. Rothenberg is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Esophagitis, Viral Gastroenteritis, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Tissue Biopsy. Dr. Rothenberg is currently accepting new patients.

Frequently Asked Questions about Dr. Julie S. Shepard

How do I make an appointment with Dr. Julie S. Shepard?

You can book an appointment with Dr. Julie S. Shepard by calling their office at 937-424-9294. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julie S. Shepard a top-rated expert for Measles?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julie S. Shepard is classified as an Experienced expert for Measles, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julie S. Shepard specialize in?

While Dr. Julie S. Shepard is a Pediatrics, they have specific expertise in Measles. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Julie S. Shepard participate in research or clinical trials?

Yes. Dr. Julie S. Shepard has published 10 articles and abstracts on conditions like Measles. You can view a list of Dr. Julie S. Shepard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julie S. Shepard accept my insurance?

Dr. Julie S. Shepard accepts most major insurance plans, including Anthem BCBS and Humana. We recommend calling the office directly at 937-424-9294 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shepard's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile